Naproxen

BreastfeedingGeriatricPediatric
  • TRADE NAMES: Aleve (Bayer); Anaprox; Apranax; Dymenalgit; Flanax; Laraflex; Naprelan; Naprogesic; Napron X; Naprosyn (Roche); Naprosyne; Naxen; Novo-Naprox; Nu-Naprox; Supradol; Synflex (Roche); Velsay
  • INDICATIONS: Pain, arthritis
  • CLASS: Covid-19 putative drug, Non-steroidal anti-inflammatory (NSAID)
  • HALF-LIFE: 15 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Methotrexate, Methyl salicylate, Prednisolone

PREGNANCY CATEGORY: C

Under investigation for treating COVID-19

See adverse reactions attributed to class:

Covid-19 putative drug

Non-steroidal anti-inflammatory (NSAID)

NSAIDs may cause an increased risk of serious cardiovascular and gastrointestinal adverse events, which can be fatal. This risk may increase with duration of use.

Anaphylactoid reactions / anaphylaxis (includes anaphylactic shock) <1%

(2014): Faria E+, J Investig Allergol Clin Immunol 24(1), 40 (1 case)

(2005): Klote MM+, Allergy 60(2), 260

Angioedema <1%

(2014): Venci JV+, Ann Allergy Asthma Immunol 113(6), 666

(2011): Cimbollek S+, J Investig Allergol Clin Immunol 21(6), 488

(2010): Prlesi L+, Am J Health Syst Pharm 67(16), 1351 (with quinapril)

(2000): Ghislain PD+, Ann Med Interne (Paris) 151, 227 (nuchal scalp)

(1984): Stern RS+, JAMA 252, 1433

Bullous dermatosis 

(2004): Leivo T+, Br J Dermatol 151(1), 232

(1996): Gonzalo-Garijo MA+, Allergol Immunopathol Madr (Spanish) 24, 89

(1990): Suarez SM+, Arthritis Rheum 33, 903 [REVIEW]

(1989): Rivers JK+, Med J Aust 151, 167

(1984): Stern RS+, JAMA 252, 1433

Diaphoresis <3%

(1990): Todd PA+, Drugs 40, 91 [REVIEW]<3%

(1985): Bigby M+, J Am Acad Dermatol 12, 866 [REVIEW]

(1982): Bailin PL+, Clin Rheum Dis 8, 493 [REVIEW] (passim)

DRESS syndrome 

(2016): Silva SA+, Rev Assoc Med Bras 62(3), 227 [REVIEW]

(2010): Pinana E+, J Clin Pharm Ther 35(3), 365Pediatric (with sulfasalazine)

(2006): Condat B+, Gastroenterol Clin Biol 30(1), 142 (with sulfasalazine)

(2006): Teo L+, Singapore Med J 47(3), 237

Erythema 

(2016): Plapler PG+, Drug Des Devel Ther 10, 19871%

Erythema multiforme <1%

(1985): Bigby M+, J Am Acad Dermatol 12, 866 [REVIEW]

(1984): Stern RS+, JAMA 252, 1433

Erythema nodosum 

(1990): Todd PA+, Drugs 40, 91 [REVIEW]

Exanthems <14%

(2012): Stern RS, N Engl J Med 366(26), 2492 (with lamotrigine and thyroxine)

(1990): Todd PA+, Drugs 40, 91 [REVIEW]

(1985): Bigby M+, J Am Acad Dermatol 12, 866 [REVIEW]

(1984): Stern RS+, JAMA 252, 1433

(1979): Brogden RN+, Drugs 18, 241 [REVIEW]

(1978): Castles JJ+, Arch Intern Med 138, 3625%

(1976): Dyer HR, Ann Intern Med 84, 221

(1975): Bowers DE+, Ann Intern Med 83, 47014%

(1975): Brogden RN+, Drugs 9(5), 326 [REVIEW]

Facial scarring 

(2001): Wallace CA+, J Am Acad Dermatol 45, 746 (in children)

Fixed eruption 

(2018): Bakhtiari S+, Clujul Med 91(1), 27 [REVIEW]

(2017): Garcia D+, Expert Rev Clin Pharmacol 10(7), 717 [REVIEW] (passim)

(2016): Noguerado-Mellado B+, Recent Pat Inflamm Allergy Drug Discov 10(1), 61

(2014): Mokhtari F+, J Res Med Sci 19(8), 720 [REVIEW]9%

(2012): Bilgili S+, Hum Exp Toxicol 31(2), 197 (2 cases)

(2011): Akyazi H+, Hum Exp Toxicol 30(11), 1872

(2011): Perez-Calderon R+, J Investig Allergol Clin Immunol 21(2), 153

(2009): Bandino JP+, Dermatol Online J 15(11), 4 (generalized bullous)

(2009): Banerjee T+, Indian Pediatr 46(5), 432 (pustular)

(2009): Gendernalik SB+, Cutis 84(4), 215 (passim)

(2006): Nnoruka EN+, Int J Dermatol 45(9), 10623%

(2005): Ozkaya E+, J Am Acad Dermatol 53(1), 178

(2004): Leivo T+, Br J Dermatol 151(1), 232

(2004): Ozkaya-Bayazit E, Clin Exp Dermatol 29(4), 419

(2003): Ozkaya-Bayazit E, J Am Acad Dermatol 49(6), 100324%

(2002): Li H+, Int J Dermatol 41(2), 96

(2001): Gonzalo MA+, Br J Dermatol 144(6), 1291

(2000): Ozkaya-Bayazit E+, Eur J Dermatol 10, 288

(1996): Enta T, Can Fam Physician 42, 1099

(1996): Gonzalo-Garijo MA+, Allergol Immunopathol Madr (Spanish) 24, 89

(1991): Shelley WB+, Cutis 48, 368 (observation)

(1990): Black AK+, Br J Dermatol 123, 277 (observation)

(1990): Todd PA+, Drugs 40, 91 [REVIEW]

(1987): Habbema L+, Dermatologica 174, 184

(1985): Bigby M+, J Am Acad Dermatol 12, 866 [REVIEW]

(1984): Stern RS+, JAMA 252, 1433

Herpes simplex 

(2014): Sieper J+, Ann Rheum Dis 73(1), 1012% (oral / with infliximab)

Hot flashes / hot flushes <1%

(2016): Syed YY, Drugs 76(1), 111 [REVIEW] (with sumatriptan)

Hypersensitivity 

(2013): Perez-Ezquerra PR+, Ann Allergy Asthma Immunol 111(1), 74 (with nabumetone)

(2001): McMahon AD+, J Clin Epidemiol 54(12), 1271

Lichen planus 

(2006): Gunes AT+, Int J Dermatol 45(6), 709

(1999): Acta Derm Venereol (Stockh) 79, 329 (bullous)

(1984): Heymann WR+, J Am Acad Dermatol 10, 299

Lichenoid eruption 

(1996): Shelley WB+, Cutis 60, 20

(1990): Todd PA+, Drugs 40, 91 [REVIEW]

(1985): Bigby M+, J Am Acad Dermatol 12, 866 [REVIEW]

Linear IgA bullous dermatosis 

(2000): Bouldin MB+, Mayo Clin Proc 75(9), 967 [REVIEW]

Lupus erythematosus 

(2004): Ting W+, Lupus 13(12), 941 [REVIEW]

(1992): Parodi A+, JAMA 268, 51

Photosensitivity <1%

(2011): Gutierrez-Gonzalez E+, Photodermatol Photoimmunol Photomed 27(6), 338

(1996): Becker L+, Acta Derm Venereol 76(5), 337

(1994): Berger TG+, Arch Dermatol 130, 609 (in HIV-infected)

(1991): Allen R+, J Rheumatol 18, 893

(1991): Lutzow-Holm C, Tidsskr Nor Laegeforen (Norwegian) 111, 2739

(1990): Suarez SM+, Arthritis Rheum 33, 903 [REVIEW]

(1990): Todd PA+, Drugs 40, 91 [REVIEW]

(1989): Kaidbey KH+, Arch Dermatol 125, 783

(1989): Rivers JK+, Med J Aust 151, 167

(1987): Sterling JC+, Br J Rheumatol 26, 210

(1986): Judd LE+, Arch Dermatol 122, 451

(1986): Mayou S+, Br J Dermatol 114, 519

(1986): Shelley WB+, Cutis 38, 169

(1986): Szczeklik A, Drugs 32 (Suppl 4), 148 [REVIEW]

(1985): Farr PM+, Lancet 1, 1166

(1983): Diffey BL+, Br J Rheumatol 22, 239

Phototoxicity 

(1989): Kaidbey KH+, Arch Dermatol 125, 783

Pityriasis rosea 

(1993): Yosipovitch G+, Harefuah (Hebrew) 124, 198; 247

Pruritus (itching) 3–17%

(1990): Todd PA+, Drugs 40, 91 [REVIEW]

(1985): Bigby M+, J Am Acad Dermatol 12, 866 [REVIEW]14%

(1982): Bailin PL+, Clin Rheum Dis 8, 493 [REVIEW] (passim)

(1978): Castles JJ+, Arch Intern Med 138, 362

(1975): Bowers DE+, Ann Intern Med 83, 47017%

Pseudolymphoma 

(2001): Werth V, Dermatol Online J 7(1)

Purpura <3%

  • Purpura (naproxen)

(1985): Bigby M+, J Am Acad Dermatol 12, 866 [REVIEW]

(1982): Bailin PL+, Clin Rheum Dis 8, 493 [REVIEW] (passim)

(1979): Brogden RN+, Drugs 18, 241 [REVIEW]

(1975): Brogden RN+, Drugs 9(5), 326 [REVIEW]

Pustules 

(1989): Grattan CEH, Dermatologica 179, 57

(1986): Page SR+, BMJ 293, 510

Rash 3–9%

(2002): Bandyopadhyay P+, Int J Clin Pract 56(2), 145

(1995): Knulst AC+, Br J Dermatol 133, 647

Serum sickness-like reaction 

(2016): Koransky R+, J Allergy Clin Immunol Pract 4(1), 160

Stevens-Johnson syndrome <1%

(package insert)

(2016): Reynoso-von Drateln C+, Drug Saf Case Rep 3(1), 9 (fatal / 1 case)FatalGeriatric

Toxic epidermal necrolysis (Lyell's syndrome) <1%

(2016): Reynoso-von Drateln C+, Drug Saf Case Rep 3(1), 9 (fatal / 1 case)FatalGeriatric

(2012): Noordally SO+, Ann Saudi Med 32(3), 309 (fatal)Fatal (with atorvastatin)

(2005): Mansur AT+, Photodermatol Photoimmunol Photomed 21(2), 100

(2004): Ting W+, Lupus 13(12), 941 [REVIEW]

(1993): Correia O+, Dermatology 186, 32

Urticaria / hives <5%

(2011): Cimbollek S+, J Investig Allergol Clin Immunol 21(6), 488

(2003): Zembowicz A+, Arch Dermatol 139(12), 1577 (aspirin-induced)

(1985): Bigby M+, J Am Acad Dermatol 12, 866 [REVIEW]

(1984): Stern RS+, JAMA 252, 1433

(1979): Brogden RN+, Drugs 18, 241 [REVIEW]

(1975): Brogden RN+, Drugs 9(5), 326 [REVIEW]

Vasculitis (angiitis) / cutaneous vasculitis (angiitis) 

(1996): Lossos IS+, Harefuah (Hebrew) 130, 600

(1992): Jahangiri M+, Postgrad Med J 68, 766

(1992): Veraguth AJ+, Schweiz Med Wochenschr (German) 122, 923

(1990): Todd PA+, Drugs 40, 91 [REVIEW] (necrotizing venulitis)

(1989): Singhal PC+, Ann Allergy 63, 107

(1985): Bigby M+, J Am Acad Dermatol 12, 866 [REVIEW]

(1980): Mordes JP, Arch Intern Med 140, 985

(1979): Brogden RN+, Drugs 18, 241 [REVIEW]

(1979): Grennan DM+, N Z Med J 89, 48

Alopecia / hair loss <1%

(1990): Todd PA+, Drugs 40, 91 [REVIEW]<1%

(1989): Barter AC, BMJ 298, 325

(1989): Barth JH, BMJ 298, 675

Pyogenic granuloma 

(1994): Shelley WB+, Cutis 53, 36 (observation)

Oral mucosal fixed eruption 

(2013): Ozkaya E, J Am Acad Dermatol 69(2), e51

Stomatitis (oral mucositis) <3%

(package insert)

Tonsillitis 

(2014): Sieper J+, Ann Rheum Dis 73(1), 1012% (with infliximab)

Xerostomia (dry mouth) 

(2016): Syed YY, Drugs 76(1), 111 [REVIEW] (with sumatriptan)

(2014): Silberstein S+, Cephalalgia 34(4), 2682% (with sumatriptan)

Cardiotoxicity 

(2014): Angiolillo DJ+, J Thromb Thrombolysis 38(1), 111%

Chest pain 

(2011): McDonald SA+, Headache 51(9), 13743%Pediatric (with sumatriptan)

(2009): Mathew NT+, Headache 49(7), 971 (with sumatriptan)

Myocardial infarction 

(2012): Abuzetun JY+, J Cardiovasc Med (Hagerstown) 13(7), 471

(2010): Gudbjornsson B+, Eur J Clin Pharmacol 66(6), 619

Depression 

(2014): Essex MN+, Int J Gen Med 7, 2273%

Pain 

(2016): Syed YY, Drugs 76(1), 111 [REVIEW] (with sumatriptan)

Paresthesias 

(2016): Syed YY, Drugs 76(1), 111 [REVIEW] (with sumatriptan)

Somnolence (drowsiness) 

(2016): Plapler PG+, Drug Des Devel Ther 10, 19876%

(2016): Syed YY, Drugs 76(1), 111 [REVIEW] (with sumatriptan)

Vertigo / dizziness 

(2016): Syed YY, Drugs 76(1), 111 [REVIEW] (with sumatriptan)

(2015): Tajti J+, Expert Opin Drug Saf 14(6), 891

(2014): Silberstein S+, Cephalalgia 34(4), 2684% (with sumatriptan)

(2011): McDonald SA+, Headache 51(9), 13743%Pediatric (with sumatriptan)

(2009): Mannix LK+, Obstet Gynecol 114(1), 106 (with sumatriptan)

(2008): Silberstein SD+, Neurology 71(2), 114<2%

Inappropriate secretion of antidiuretic hormone (SIADH) 

(2020): Chiu CY+, Am J Case Rep 21, e926561 (1 case / female)Geriatric (with citalopram)

Porphyria cutanea tarda 

(1992): Shelley WB+, Advanced Dermatologic Diagnosis WB Saunders, 414 (passim)

Pseudoporphyria 

(2007): Schad SG+, Arthritis Res Ther 9(1), R10

(2002): LaDuca JR+, J Cutan Med Surg 6(4), 320

(2002): McNail S+, Arch Dermatol 138(12), 1607

(2002): Schad SG+, Hautarzt 53(1), 51

(2001): Maerker JM+, Hautarzt 52(11), 1026

(2000): De Silva B+, Pediatr Dermatol 17, 480

(1999): Al-Khenaizan S+, J Cutan Med Surg 3, 162 [REVIEW]

(1995): Creemers MC+, Scand J Rheumatol 24, 185 [REVIEW]

(1995): Girschick HJ+, Scand J Rheumatol 24, 108

(1994): Lang BA+, J Pediatr 124, 639

(1992): Cox NH+, Br J Dermatol 126, 86

(1992): Petersen CS+, Ugeskr Laeger (Danish) 154, 1713

(1991): Allen R+, J Rheumatol 18, 893

(1991): Lutzow-Holm C, Tidsskr Nor Laegeforen 111(22), 2739

(1990): Levy ML+, J Pediatr 117, 660

(1990): Sternberg A, Acta Derm Venereol 70, 354

(1990): Suarez SM+, Arthritis Rheum 33, 903 [REVIEW]

(1990): Todd PA+, Drugs 40, 91 [REVIEW]

(1989): Kaidbey KH+, Arch Dermatol 125, 783

(1988): Diffey BL+, Clin Exp Dermatol 13, 207

(1987): Burns DA, Clin Exp Dermatol 12, 296

(1987): Nicholls D, N Z Med J 100, 427

(1987): Shelley ED+, Cutis 40, 314

(1987): Sterling JC+, Br J Rheumatol 26, 210

(1987): Taylor BJ+, N Z Med J 100, 322

(1986): Judd LE+, Arch Dermatol 122, 451

(1986): Mayou S+, Br J Dermatol 114, 519

(1985): Farr PM+, Lancet 1, 1166

(1985): Howard AM+, Lancet 1, 819

Abdominal pain 

(2015): Tajti J+, Expert Opin Drug Saf 14(6), 891

(2014): Essex MN+, Int J Gen Med 7, 2273%

(2011): Mallen SR+, Curr Med Res Opin 27(7), 1359

(2005): Yilmaz H+, Turk J Gastroenterol 16(3), 138

Cholestasis 

(2011): Ali S+, Hepatobiliary Pancreat Dis Int 10(5), 552

Constipation 

(2011): Mallen SR+, Curr Med Res Opin 27(7), 1359

(2005): Yilmaz H+, Turk J Gastroenterol 16(3), 1381%

Diarrhea 

(2016): Plapler PG+, Drug Des Devel Ther 10, 19872%

(2011): Mallen SR+, Curr Med Res Opin 27(7), 1359

(1993): Eversmeyer W+, Am J Med 95(2A), 10S

Dyspepsia / functional dyspepsia / gastroparesis 

(2019): Kyeremateng K+, Curr Med Res Opin Apr, Epub ahead of print

(2016): Plapler PG+, Drug Des Devel Ther 10, 19876%

(2016): Syed YY, Drugs 76(1), 111 [REVIEW] (with sumatriptan)

(2015): Tajti J+, Expert Opin Drug Saf 14(6), 891

(2014): Essex MN+, Int J Gen Med 7, 2274%

(2014): Sieper J+, Ann Rheum Dis 73(1), 1011% (with infliximab)

(2011): Mallen SR+, Curr Med Res Opin 27(7), 1359

(2005): Yilmaz H+, Turk J Gastroenterol 16(3), 138

(2001): Cha HS+, Int J Clin Pharmacol Ther 39(12), 539

(1993): Eversmeyer W+, Am J Med 95(2A), 10S

Enteropathy 

(2013): Racz I+, World J Gastroenterol 19(6), 889

Flatulence 

(2011): Mallen SR+, Curr Med Res Opin 27(7), 1359

Gastroenteritis 

(2014): Sieper J+, Ann Rheum Dis 73(1), 1013% (with infliximab)

Gastrointestinal disorder / discomfort 

(2019): Kyeremateng K+, Curr Med Res Opin Apr, Epub ahead of print

(2012): Essex MN+, J Int Med Res 40(4), 135715%

Hepatitis 

(2011): Ali S+, Hepatobiliary Pancreat Dis Int 10(5), 552

Hepatotoxicity / liver injury / acute liver injury / drug-induced liver injury (DILI) 

(2017): Shahbaz O+, Expert Opin Drug Metab Toxicol 13(9), 935 [REVIEW]

(2015): Ash MM+, Int J Dermatol 54(3), 370 [REVIEW] (with aspirin and vismodegib)

(2014): Sieper J+, Ann Rheum Dis 73(1), 1011% (with infliximab)

(2011): Ali S+, Hepatobiliary Pancreat Dis Int 10(5), 552

Nausea 

(2016): Plapler PG+, Drug Des Devel Ther 10, 19872%

(2016): Syed YY, Drugs 76(1), 111 [REVIEW] (with sumatriptan)

(2015): Tajti J+, Expert Opin Drug Saf 14(6), 891

(2014): Silberstein S+, Cephalalgia 34(4), 2682% (with sumatriptan)

(2012): Derosier F+, Headache 52(4), 5302% (with sumatriptan)

(2011): Mallen SR+, Curr Med Res Opin 27(7), 1359

(2011): McDonald SA+, Headache 51(9), 13747%Pediatric (with sumatriptan)

(2009): Mannix LK+, Obstet Gynecol 114(1), 106 (with sumatriptan)

(2008): Silberstein SD+, Neurology 71(2), 114<4% (with sumatriptan)

(2005): Yilmaz H+, Turk J Gastroenterol 16(3), 1385%

Vomiting  

(2016): Plapler PG+, Drug Des Devel Ther 10, 19873%

Cystitis 

(2014): Sieper J+, Ann Rheum Dis 73(1), 1014%

Bleeding 

(2016): Kontogiorgis C+, Curr Vasc Pharmacol 14(6), 502 [REVIEW]

Methemoglobinemia 

(2014): Lee WS+, Am J Emerg Med 32(11), Epub

Thrombocytopenia 

(2014): Ranieri MM+, Pharmacotherapy 34(2), e14

(2010): Reese JA+, Blood 116(12), 2127

Asthenia / fatigue 

(2014): Sieper J+, Ann Rheum Dis 73(1), 108

Back pain 

(2014): Sieper J+, Ann Rheum Dis 73(1), 108

Leg cramps 

(2012): Allen RE+, Am Fam Physician 86(4), 350 [REVIEW]

Muscle spasm 

(2016): Syed YY, Drugs 76(1), 111 [REVIEW] (with sumatriptan)

Rhabdomyolysis 

(2012): Noordally SO+, Ann Saudi Med 32(3), 309 (fatal)Fatal (with atorvastatin)

Periorbital edema 

(2010): Balas M+, Am J Health Syst Pharm 67(11), 906Geriatric

Tinnitus 

(2015): Tajti J+, Expert Opin Drug Saf 14(6), 891

(1998): McKinnon BJ+, Mil Med 163(11), 792 (passim)

Nephrotoxicity / kidney injury / acute kidney injury (AKI) / drug-induced kidney injury 

(2013): Nawaz FA+, Am J Kidney Dis 62(5), 1012

(2013): Poussel M+, Presse Med 42(9 Pt 1), 1274

(2010): Dixit M+, Pharmaceuticals (Basel) 3(4), 1279 [REVIEW]

Bronchitis 

(2014): Sieper J+, Ann Rheum Dis 73(1), 1012%

Nasopharyngitis 

(2016): Syed YY, Drugs 76(1), 111 [REVIEW] (with sumatriptan)

(2014): Sieper J+, Ann Rheum Dis 73(1), 1018%

Rhinitis 

(2014): Sieper J+, Ann Rheum Dis 73(1), 108

Tuberculosis 

(2014): Sieper J+, Ann Rheum Dis 73(1), 1011% (with infliximab)

Adverse effects 

(2019): Levin OS+, Zh Nevrol Psikhiatr Im S S Korsakova (Russian) 119(5), 276%

(2018): Friedman BW+, Ann Emerg Med 71(3), 34817%

(2016): Frazer K+, J Fam Pract 65(6), 404 (with acetaminophen/oxycodone or cyclobenzaprine)

(2016): Hartling L+, Pain Res Manag Dec, Epub [REVIEW]Pediatric

(2014): Angiolillo DJ+, J Thromb Thrombolysis 38(1), 1120–37% (gastrointestinal)

(2014): Pellicano R, Minerva Gastroenterol Dietol 60(4), 255 [REVIEW] (gastrointestinal)

(2013): Law S+, Cochrane Database Syst Rev 10, CD008541 [REVIEW] (with sumatriptan)

(2012): Derosier F+, Headache 52(4), 53012% (with sumatriptan)

(2012): Essex MN+, J Int Med Res 40(4), 1357 (gastrointestinal)

(2011): Chang CH+, Pharmacoepidemiol Drug Saf 20(7), 763 (gastrointestinal)

(2010): Berges A+, Clin Ther 32(6), 1165 (with sumatriptan)

(2003): Shi W+, Zhonghua Liu Xing Bing Xue Za Zhi (Chinese) 24(11), 1044 [REVIEW]29%

Breast cancer 

(2014): Sieper J+, Ann Rheum Dis 73(1), 1011% (with infliximab)

Death 

(2016): Reynoso-von Drateln C+, Drug Saf Case Rep 3(1), 9 (1 case)Geriatric

(2012): Noordally SO+, Ann Saudi Med 32(3), 309 (with atorvastatin)

Infection 

(2014): Sieper J+, Ann Rheum Dis 73(1), 1014%

Side effects 5–9%

(1990): Todd PA+, Drugs 40, 91 [REVIEW] (up to 9%)

(1985): Bigby M+, J Am Acad Dermatol 12, 866 [REVIEW]<5%

(1974): Cuthbert MF, Curr Med Res Opin 2, 6005%



Adverse reactions attributed to entire drug class Covid-19 putative drug

Cardiovascular adverse effect 

(2020): Carpenter A+, Front Cardiovasc Med 7, 85 [REVIEW]

(2020): Giudicessi JR+, Mayo Clin Proc May, Online ahead of print [REVIEW]

(2020): Naksuk N+, Eur Heart J Acute Cardiovasc Care May, Epub ahead of print [REVIEW]

(2020): Sarayani A+, Res Social Adm Pharm Apr, Epub ahead of print [REVIEW]

(2020): Zhang D+, Zhongguo Zhong Yao Za Zhi (Chinese) 45(10), 2275-2286 [REVIEW]

Neuropsychiatric / neuropsychological adverse effect 

(2021): Borah P+, Front Mol Biosci 8, 627723

(2020): García CAC+, Gen Hosp Psychiatry Jun, Online ahead of print [REVIEW]

Gastrointestinal disorder / discomfort 

(2020): Sun J+, Clin Pharmacol Ther Apr, Epub ahead of print23%

Thrombocytopenia 

(2020): Nham E+, Infect Chemother Apr, Epub ahead of print

Adverse effects 

(2021): Bérard A+, PLoS One 16(5), e0251746 [REVIEW] (in pregnancy)

(2021): Cheng Q+, Aging (Albany NY) Sep, Online ahead of print [REVIEW]

(2021): Cruciani F+, Recenti Prog Med 112(3), 195-206 [REVIEW]

(2021): Ommati MM+, J Biochem Mol Toxicol May, Online ahead of print [REVIEW]

(2021): Qiu R+, Medicine (Baltimore) 100(16), e25532 [REVIEW]

(2021): Wu SS+, Chin Med J (Engl) Jul, Online ahead of print [REVIEW]

(2020): Favilli A+, J Matern Fetal Neonatal Med Jun, Online ahead of print [REVIEW]

(2020): Griffiths G+, Trials 21(1), 544

(2020): Patil VM+, Life Sci May, Epub ahead of print [REVIEW]

(2020): Rhodes NJ+, medRxiv Jun, Preprint

(2020): Sun J+, Clin Pharmacol Ther Apr, Epub ahead of print38%

(2020): Svensson M, Lakartidningen (Swedish) Apr, 117

(2020): Wen CY+, Zhonghua Nei Ke Za Zhi (Chinese) May, Epub ahead of print

(2020): Zekarias A+, Drug Saf Sep, Online ahead of print [REVIEW]

(2020): Zhong H+, Pharmacol Res Apr, Epub ahead of print [REVIEW]

Adverse reactions attributed to entire drug class Non-steroidal anti-inflammatory (NSAID)

Angioedema 

(2017): Dona I+, Allergy 72(9), 1346

(2014): Dona I+, J Investig Allergol Clin Immunol 24(3), 143

DRESS syndrome 

(2017): Matta JM+, An Bras Dermatol 92(1), 30 [REVIEW] (passim)

Exanthems 

(2015): Farshchian M+, Clin Cosmet Investig Dermatol 8, 539%

Fixed eruption 

(2015): Farshchian M+, Clin Cosmet Investig Dermatol 8, 5316%

Hypersensitivity 

(2014): Dona I+, J Investig Allergol Clin Immunol 24(3), 143 [REVIEW]

(2010): Um SJ+, J Investig Allergol Clin Immunol 20(7), 55613%

Lupus erythematosus 

(2012): Dalle Vedove C+, J Dtsch Dermatol Ges 10(12), 889 [REVIEW]

Photosensitivity 

(2017): Lugovic-Mihic L+, Acta Clin Croat 56(2), 277 [REVIEW]

(2016): Zuba EB+, Acta Dermatovenerol Croat 24(1), 55 [REVIEW]

Rash 

(2017): Eccleston C+, Cochrane Database Syst Rev 8, CD012537 [REVIEW]Pediatric

Stevens-Johnson syndrome 

(2011): Barvaliya M+, J Postgrad Med 57(2), 11522%

(2011): Ferrandiz-Pulido C+, Med Clin (Barc) 136(13), 583

(2011): Singalavanija S+, J Med Assoc Thai 94 Suppl 3, S855%

Toxic epidermal necrolysis (Lyell's syndrome) 

(2011): Barvaliya M+, J Postgrad Med 57(2), 11522%

(2011): Ferrandiz-Pulido C+, Med Clin (Barc) 136(13), 583

Urticaria / hives 

(2017): Dona I+, Allergy 72(9), 1346

(2015): Farshchian M+, Clin Cosmet Investig Dermatol 8, 5327%

(2014): Dona I+, J Investig Allergol Clin Immunol 24(3), 143

Cardiotoxicity 

(2018): Wongrakpanich S+, Aging Dis 9(1), 143 [REVIEW]

(2017): Varga Z+, Cureus 9(4), e1144 [REVIEW]

Hypertension 

(2017): Varga Z+, Cureus 9(4), e1144 [REVIEW]

(2015): Richette P+, Expert Opin Drug Saf 14(8), 1259 [REVIEW]

Headache 

(2017): Eccleston C+, Cochrane Database Syst Rev 8, CD012537 [REVIEW]Pediatric

Vertigo / dizziness 

(2017): Eccleston C+, Cochrane Database Syst Rev 8, CD012537 [REVIEW]Pediatric

Abdominal pain 

(2017): Eccleston C+, Cochrane Database Syst Rev 8, CD012537 [REVIEW]Pediatric

Constipation 

(2017): Eccleston C+, Cochrane Database Syst Rev 8, CD012537 [REVIEW]Pediatric

Diarrhea 

(2017): Eccleston C+, Cochrane Database Syst Rev 8, CD012537 [REVIEW]Pediatric

(2015): Koffeman AR+, Scand J Prim Health Care 33(3), 1638%

Dyspepsia / functional dyspepsia / gastroparesis 

(2017): Yang M+, Curr Med Res Opin 33(6), 973 [REVIEW]

(2015): Koffeman AR+, Scand J Prim Health Care 33(3)_, 16334%

Gastric obstruction 

(2017): Yang M+, Curr Med Res Opin 33(6), 973 [REVIEW]

Gastrointestinal adverse reaction 

(2021): McEvoy L+, Front Pharmacol Jun, eCollection [REVIEW]

Gastrointestinal bleeding 

(2018): Chi TY+, Medicine (Baltimore) 97(18), e0665

(2018): Wongrakpanich S+, Aging Dis 9(1), 143 [REVIEW]

(2017): Yang M+, Curr Med Res Opin 33(6), 973 [REVIEW]

(2016): Cardile S+, World J Gastroenterol 22(5), 1877Pediatric

(2016): Venerito M+, Pharmaceuticals (Basel) 3(7), 2225 [REVIEW]

Gastrointestinal ulceration 

(2017): Chinese Rheumatism Data Center, Zhonghua Nei Ke Za Zhi (Chinese) 56(1), 81

Nausea 

(2017): Eccleston C+, Cochrane Database Syst Rev 8, CD012537 [REVIEW]Pediatric

Peptic ulceration 

(2013): Sinha M+, Mediators Inflamm Mar, Epub [REVIEW]

Nephrotoxicity / kidney injury / acute kidney injury (AKI) / drug-induced kidney injury 

(2018): Wongrakpanich S+, Aging Dis 9(1), 143 [REVIEW]

(2016): Vuckovic S+, Curr Med Chem 23(19), 1953

(2015): Jung JH+, BMC Res Notes 8(1), 793

(2015): Richette P+, Expert Opin Drug Saf 14(8), 1259 [REVIEW]

Dyspnea / shortness of breath 

(2015): Koffeman AR+, Scand J Prim Health Care 33(3), 1638%

Adverse effects 

(2016): Gerosa M+, Expert Opin Pharmacother 17(11), 1539 [REVIEW] (in pregnancy)

(2016): Walters KM+, Immunol Allergy Clin North Am 36(4), 625 [REVIEW]

(2016): Wong YJ, Evid Based Dent 17(3), 83 [REVIEW]3–44%

(2015): Drago F+, Int J Clin Pharm 37(5), 739 (cutaneous)

(2015): Richette P+, Expert Opin Drug Saf 14(8), 1259 [REVIEW] (gastrointestinal)

(2015): Tian XY+, Arch Dermatol Res 307(9), 82919% (cutaneous)

(2014): Carter GT+, Phys Med Rehabil Clin N Am 25(2), 457 [REVIEW]

Page last updated 08/02/2021

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top